A similar accumulation (though to a lesser extent) was observed in RES-CRC-SCs treated with CHK1+RAD51 inhibitors, while prexasertib, mirin and B02 monotherapies did not significantly affect cell cycle progression (Figure 3A,B). This evidence concerns the gene RAD51 and colorectal carcinoma.